Natera, Inc. $NTRA Stake Reduced by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. trimmed its holdings in Natera, Inc. (NASDAQ:NTRA) by 25.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,284 shares of the medical research company’s stock after selling 5,615 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Natera were worth $3,731,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC lifted its stake in Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth boosted its holdings in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in Natera during the second quarter worth approximately $298,000. Finally, WINTON GROUP Ltd bought a new stake in Natera during the second quarter worth approximately $558,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Natera

In other news, insider John Fesko sold 1,438 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92. Following the completion of the sale, the insider directly owned 185,782 shares of the company’s stock, valued at $37,684,020.88. This trade represents a 0.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $218.43, for a total value of $655,290.00. Following the sale, the insider directly owned 137,643 shares of the company’s stock, valued at $30,065,360.49. This trade represents a 2.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 159,378 shares of company stock worth $34,640,860. 5.05% of the stock is currently owned by corporate insiders.

Natera Price Performance

NTRA opened at $212.07 on Monday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The business has a 50-day moving average of $206.49 and a 200-day moving average of $215.83. The company has a market capitalization of $30.37 billion, a PE ratio of -130.10 and a beta of 1.56.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NTRA. Wolfe Research started coverage on Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective for the company. BTIG Research cut their price objective on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Piper Sandler reiterated an “overweight” rating and set a $249.00 price objective on shares of Natera in a research report on Tuesday, May 12th. Morgan Stanley cut their target price on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Finally, Robert W. Baird set a $265.00 price target on Natera in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus target price of $256.53.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.